{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:22:06Z","timestamp":1769095326155,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.jinf.2007.08.007","type":"journal-article","created":{"date-parts":[[2007,11,17]],"date-time":"2007-11-17T07:11:43Z","timestamp":1195283503000},"page":"484-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients"],"prefix":"10.1016","volume":"55","author":[{"given":"Edsel Maurice T.","family":"Salvana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Salata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2007.08.007_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous disease and TNF antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2007.08.007_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","article-title":"TNF-blocking agents and tuberculosis: new drugs illuminate an old topic","volume":"44","author":"Keane","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jinf.2007.08.007_bib3","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar1994","article-title":"Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists","volume":"8","author":"Hamdi","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jinf.2007.08.007_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2007.08.007_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/rheumatology\/keh700","article-title":"Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab","volume":"44","author":"Marie","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jinf.2007.08.007_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2005.06.006","article-title":"Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use","volume":"53","author":"Mufti","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2007.08.007_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/s10165-004-0360-z","article-title":"Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab","volume":"15","author":"Okubo","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jinf.2007.08.007_bib8","first-page":"723","article-title":"Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis","volume":"24","author":"Boulman","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jinf.2007.08.007_bib9","first-page":"67","article-title":"The immune reconstitution inflammatory syndrome","volume":"5","author":"Shelburne","year":"2003","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jinf.2007.08.007_bib10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/427941","article-title":"Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis","volume":"40","author":"Garcia-Vidal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2007.08.007_bib11","first-page":"1057","article-title":"Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab","volume":"9","author":"Belknap","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jinf.2007.08.007_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2007.08.007_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jinf.2007.08.007_bib14","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2007.08.007_bib15","unstructured":"American College of Rheumatology Hotline. FDA advisory committee reviews safety of TNF inhibitors, Available from: <http:\/\/www.rheumatology.org> [accessed on 28.12.06]."},{"key":"10.1016\/j.jinf.2007.08.007_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"Mow","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jinf.2007.08.007_bib17","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1378\/chest.122.5.1858","article-title":"Lung injury linked to etanercept therapy","volume":"122","author":"Peno-Green","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2007.08.007_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/art1.10243","article-title":"Experience with etanercept in an academic medical center: are infection rates increased?","volume":"47","author":"Phillips","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jinf.2007.08.007_bib19","doi-asserted-by":"crossref","first-page":"944S","DOI":"10.1378\/chest.126.4_MeetingAbstracts.944S","article-title":"Fatal pulmonary nontuberculous mycobacterial infection in a patient receiving etanercept for rheumatoid arthritis","volume":"126","author":"Jaffery","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2007.08.007_bib20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1378\/chest.124.3.1174","article-title":"Etanercept or Mycobacterium lung injury?","volume":"124","author":"Fennelly","year":"2003","journal-title":"Chest"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445307007529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445307007529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:32:06Z","timestamp":1758987126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445307007529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0163445307007529"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2007.08.007","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2007.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}